EUCTR2020-005165-14-DE进行中（未招募）1 期
Randomized, controlled, double-blind, multi-center trial to evaluate the
Teikoku Seiyaku Co Ltd.0 个研究点目标入组 200 人开始时间: 2021年1月11日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.acute sports-related soft-tissue injury/contusion (strains, sprains, bruises) of the upper or lower limb
- •2.location of injury such that pain-on-movement (POM) is elicited on by the exercises described in Section 7.5
- •3.enrollment within 6 hours of the injury
- •4.baseline VAS score for POM of injured extremity > 50 mm on a 100 mm VAS
- •5.size of injury, as assessed by investigator, = 25 cm2 and = 120 cm2
- •6.adult male or female patients
- •7.age 18 to 60 years
- •8.having given written informed consent
- •9.satisfactory health as determined by the Investigator based on medical history and physical examination.
- •10.Women of child-bearing potential (defined as all women physiologically capable of becoming pregnant) who are not using an acceptable method of contraception defined as:
- •Surgical sterilization
- •Hormonal contraception
- •Double barrier method
- •Periodic abstinence is NOT an acceptable method of contraception. An acceptable method of contraception must be maintained throughout the study.
- •A woman who is post-menopausal must have a negative urine pregnancy test at screening but will not need to comply with an acceptable method of contraception. Women are considered post-menopausal and not of child bearing potential if they had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or six months of spontaneous amenorrhea with serum FSH levels > 40 mIU/mL or have had surgical bilateral oophorectomy (with or without hysterectomy) at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment.
- •11.known hypersensitivity to Esflurbiprofen or one of the excipients of the patch
- •12.patients with any ongoing condition that may interfere with the absorption, distribution, metabolism, or excretion of Esflurbiprofen
- •13.history of previous significant injury to the same extremity within 6 months
- •14.patients with a disease affecting the same limb, such as synovitis, rheumatoid arthritis, arthrosis, etc.
- •15.patients having an ongoing painful condition associated with sports-related injury/contusion
- •16.patients suffering from symptoms of an infectious disease including swelling of any joint of the affected upper or lower limbs
- •17.patients who had surgery of the affected upper or lower limb within one year of study entry
- •18.patients with significant diseases (defined as a disease which, in the opinion of the investigator, may either put the patient at risk because of participation in the study or a disease which may influence the results of the study or the patient’s ability to participate in the study; includes patients with a history of gastrointestinal bleeding, significant cardiovascular, liver or renal disease).
- •19.patients with a blood coagulation disorder
- •20.patients who use any impermissible medication
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 200
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •1.significant concomitant injury in association with the index acute sports-related soft-tissue injury/contusion; e.g. fracture, nerve injury, ligament disruption, tear of muscle or cartilage, or open wound
- •2.excessively hairy skin at application site, cutting the hair in the injured site prior to patch application will qualify for inclusion
- •3.current skin disorder or shaving hair at application site
- •4.history of excessive sweating/hyperhidrosis inclusive of application site
- •5.intake of NSAIDs or analgesics within 36 hours, opioids within 7 days, or corticosteroids within 60 days of inclusion in the study
- •6.intake of long-acting NSAIDs or application of topical medication since the injury (RICE allowed)
- •7.participation in a clinical study within 30 days before inclusion in the study or concomitantly
- •8.drug or alcohol abuse in the opinion of the investigator
- •9.Pregnant and lactating women
- •10.Women of child-bearing potential (defined as all women physiologically capable of becoming pregnant) who are not using an acceptable method of contraception defined as:
- •Surgical sterilization
- •Hormonal contraception
- •Double barrier method
- •Total abstinence throughout the study at the discretion of the Investigator.
研究者
相似试验
进行中（未招募）
1 期
ocal symptomatic and short-term treatment of pain in acute strains, sprains or bruises of the extremities following blunt trauma, e.g. sports injuriesAcute blunt, soft tissue injuries of the limbsMedDRA version: 20.0Level: LLTClassification code 10041775Term: Sprains and strains of ankle and footSystem Organ Class: 100000004863MedDRA version: 20.0Level: LLTClassification code 10032894Term: Other specified sites of sprains and strainsSystem Organ Class: 100000004863MedDRA version: 20.0Level: LLTClassification code 10041777Term: Sprains and strains of elbow and forearmSystem Organ Class: 100000004863MedDRA version: 20.0Level: LLTClassification code 10041790Term: Sprains and strains of shoulder and upper armSystem Organ Class: 100000004863MedDRA version: 20.0Level: LLTClassification code 10041798Term: Sprains and strains of wrist and handSystem Organ Class: 100000004863MedDRA version: 21.0Level: LLTClassification code 10019428Term: HematomaSystem Organ Class: 100000004866EUCTR2019-001038-32-DEead Chemical Company Ltd132
进行中（未招募）
不适用
Trial to evaluate the efficacy and safety of a liquid containing ivy leaves dry extract vs. placebo in the treatment of acute coughAcute coughMedDRA version: 17.1Level: LLTClassification code 10066522Term: Acute coughSystem Organ Class: 100000004855EUCTR2014-003590-41-DEEngelhard Arzneimittel GmbH & Co.KG
尚未招募
1 期
Randomized, controlled, double-blind, multicenter, prospective clinical study and mechanism exploration of Qinggan Sanjie Xiaoying Decoction in treating Hashimoto's thyroiditisHashimoto's thyroiditisITMCTR2200006524Sun Simiao Hospital of Beijing University of traditional Chinese Medicine
进行中（未招募）
1 期
Rivaroxaban versus Aspirin in secondary prevention of stroke and prevention of systemic embolism in patients with recent embolic stroke of undetermined source (ESUS)EUCTR2013-000768-27-GRBayer HealthCare AG7,000
进行中（未招募）
1 期
Rivaroxaban versus Aspirin in secondary prevention of stroke and prevention of systemic embolism in patients with recent embolic stroke of undetermined source (ESUS)Embolic stroke of undetermined source (ESUS)MedDRA version: 18.1 Level: PT Classification code 10014498 Term: Embolic stroke System Organ Class: 10029205 - Nervous system disordersEUCTR2013-000768-27-PTBayer HealthCare AG7,213